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RU (10%). Similar impacts were observed for ES. Based on the real life dataset, a 10% 
decrease DE would lead to a range of reductions across Europe including 16% in 
Denmark, 12% in Austria, 10% in HR and 5% in Netherlands. ConClusions: Price 
reductions of branded therapies in any of the key European markets would likely 
have a significant impact on prices in other markets reducing overall profits for the 
pharmaceutical industry.
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objeCtives: As the result of the 2007 economic crisis, the number of employed 
significantly decreased. In our study we investigated how the number of people 
entitled for sick-pay, the number of days resorting to sick-pay and the number 
of sick-leave days in ratio with one sick-pay case changed in this period regard-
ing age groups and genders. Methods: We used the data of the National Health 
Insurance Fund Administration of Hungary, statistical reports of Nr. OSAP 1514, as 
well as data of Hungarian Central Statistical Office from the period from the years 
between 2005 and 2013. We analysed the number of employees entitled for sick-pay, 
the number of days spent on sick-leave. Results: In the period under investiga-
tion the number of employees entitled for sick-pay increased from 3.486 to 3.796 
thousand people, however, at the same time, the number of sick-pay cases fell 
from 1,252.000 to 825.000, and the number of days spent on sick-leave generally fell 
from 30 to 24. Women spent generally 40-56 percent more days on sick-leave which 
mostly came from childcare. Between the years of 2007 and 2009, people adhering to 
sick-pay were mostly between the ages of 30-34 (28-21%), while from 2010 between 
the ages of 35-39 (20%). This is connected to the number of people employed. From 
2009, the number of employees significantly increase in the age group 55-59 (2008: 
46,2%, 2013:58,4%), and simultaneously the number of people adhering to sick-pay 
also became higher. ConClusions: Based on the comprehensive analysis of the 
statistical data we can ascertain that adhering to sick-pay is in close connection 
with the employment ratio. Furthermore, we can say that in the period after the 
2008 economic crisis the number of days spent on sick-leave fell with 35% and the 
number of days on sick-leave fell with 20%.
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objeCtives: This paper examines the short- and long-run effect of biosimilar entry 
on price erosion. Furthermore, the impact of increases in the number of competi-
tors on prices of originators is investigated. Methods: A series of explanatory 
analyses have been performed using an econometric model which was developed 
for the years 2008–2014 spanning across 10 European countries: Bulgaria, France, 
Germany, Greece, Hungary, Italy, the Netherlands, Norway, Poland, and the UK. Two 
successful biosimilars were considered for the analyses: filgrastim and epoetins. A 
semi-structured literature review as well as a survey and interviews with country 
experts have been conducted to understand price dynamics in each market. Prices 
were obtained from country experts and verified with IMS Health. The model used 
dynamic panel data analysis, utilising Ordinary Least Squares regression with fixed 
effects, subjected to a Granger causality test. Results: The study assumes that the 
prices of currently marketed biosimilars define the attractiveness of the market and 
impact the entry decision of further competitors. This assumption was confirmed 
for epoetins, where each next biosimilar entrant in the current month leads to a 
7% (p= 0,0001) price decrease next month, with a long-run sustained effect of 4% 
(p= 0,1806). The entrance of new competitors has the highest impact on price erosion 
in Bulgaria, Italy and Poland. There is a strong trend indicating that a doubling in 
the number of competitors leads to about 10% (p= 0,1266) decrease in the originator 
prices in the long-run for filgrastim, with strongest effect in Bulgaria. This effect is 
insignificant for epoetins (p= 0,9694). ConClusions: Biosimilars manufacturers 
should carefully analyse the number of competitors planning to enter the mar-
ket when making strategic decisions on the investment in the development of 
biosimilars.
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objeCtives: In the interest of increasing transparency and access to healthcare 
utilization data, the French government has published the highly anticipated Open 
DAMIR database (Dépenses Assurance Maladie Inter-Régimes). The objective of this 
study was to perform an exploratory analysis of the DAMIR database in order to 
estimate the mean cost of each type of physician visit and the mean surcharge rate 
for technical procedures, by specialty, in order to better inform health economic mod-
eling in the French setting. Methods: The DAMIR database consists of monthly 
extractions of data from the larger French national health insurance limited-access 
database. We analyzed data collected over a 3-month period (September-November 
2014), comprising a total of 98,684,544 outpatient visits and 54,310,532 technical pro-
cedures (including outpatient and inpatient procedures, Diagnosis-Related Group 
billing excepted). Total costs were estimated from the all-payer perspective, in 
accordance with French guidelines. We calculated mean costs for each type of visit, 
including surcharges, and the mean surcharge rate for technical procedures for each 
specialty. Results: The three types of visits associated with the highest mean costs 
were for neurologists (€ 50.58 per visit), surgeons (€ 45.74), and psychiatrists (€ 43.96), 
whereas the lowest mean costs were for general practitioners (€ 24.12), nephrologists 
(€ 25,58), and geriatricians (€ 29.58). The highest surcharge rates for technical proce-
dures were billed by surgeons (mean surcharge of +55.6% of the minimum reimburs-
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objeCtives: To compare technology-specific cost-effectiveness analyses (CEA) 
submitted as part of health technology assessments (HTA) in France, England 
and Canada and to highlight the comments, criticisms and conclusions from the 
HTA agencies in order to assess the feasibility of a unified approach. Methods: 
Newly published health economic appraisals from the French National Authority 
for Health (HAS) were reviewed, analyzed and compared to technology apprais-
als and/or evidence review group (ERG) reports in other countries for the same 
drugs including sofosbuvir (Sovaldi®), trastuzumab emtansine (Kadcyla®), riociguat 
(Adempas®) and dolutegravir (Tivicay®). The analysis focused first on the review 
of methodological approach selected by the manufacturer including model type, 
time horizon, discount rates, perspective, study population, comparators as well as 
efficacy, costs and utility data and presentation of results (i.e. total costs and health 
benefit, incremental cost-effectiveness ratio from both base-case and sensitivity 
analyses). The analysis then focused on comments made by the agency committees, 
criticisms and overall conclusions. For each drug, a comparison between models 
used and agencies’ final recommendations was undertaken to highlight convergent 
and divergent points between countries. Results: Results were heterogeneous 
between drugs which made it difficult to draw a general overarching conclusion. 
Nevertheless, some points were underlined by every agency. As an example, French, 
English and Canadian HTA agencies all drew attention to small patient samples and 
their impacts on the robustness of efficacy data for subgroups in several assess-
ments, which led to uncertainty around estimates of clinical effectiveness and 
therefore cost-effectiveness. ConClusions: Cost-effectiveness analyses have been 
introduced in France as part of the assessment of new health technologies two years 
ago whereas it has been used for about 15 and 20 years in England and Canada 
respectively. This review highlighted the level of similarities between countries 
to assess the feasibility of a unified approach to prepare the submission process.
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objeCtives: Hospital pharmaceutical expenditure dropped by almost 50% after 
memorandum measures were first in place. Severe cuts imposed on targets of phar-
maceutical expenditure between 2012 and 2014, run parallel to a variety of general 
reform measures, affecting primary care and non-hospital access to pharmaceuti-
cals. The aim of this study was to isolate main achievements versus other hospital 
cost-drivers. Methods: End-year 2012-2014 invoiced data from all hospitals in 
Greece were analysed, in order to examine trends in pharmaceutical versus non-
pharmaceutical savings. Non-pharmaceutical savings included costs on appliances, 
orthopaedics and diagnostics. A separate analysis looked at total pharmaceutical 
expenditure versus costs of outsourcing services and other expendables such as 
medical gas and energy supplies. Total expenditure for pharmaceuticals was then 
compared to volumes in unit boxes for the respective years, in order to examine 
effectiveness of other reform measures, other than price erosion and discounts/
rebates offered such as electronic and INN prescribing. Results: Hospital pharma-
ceutical expenditure dropped by 31% over three years, from € 761M in 2012, to € 642M 
in 2013 and € 519M in 2014, when respective savings for orthopaedics, healthcare 
appliances and diagnostics amounting to 6%, 25% and 13% respectively (cumulative 
2014 was € 508M). Total savings due to outsourcing services and medical and energy 
supplies reached (-)26% and (-)20% respectively, with an absolute sum of € 180M over 
the three years. Regarding volumes of hospital lines for the three respective years, 
unit numbers dropped from 84,525,999, to 79,987,535 and 77,075,298 unit-boxes. 
When calculating pharmaceutical costs, hospitals spent on average € 9.00, € 8.02 and 
€ 6.74 per unit used in 2012, 2013 and 2014 respectively. ConClusions: Significant 
savings have been achieved for pharmaceuticals in the Greek hospital setting. The 
cuts were mainly attributable to improved cost/pack ratio, but a notable decrease in 
units was also observed. Percentage savings in pharmaceuticals were higher than 
respective savings achieved in other hospital cost-drivers.
PHP97
inTrOducing Orange: an inTernaTiOnal Price reference TOOl
Zah V1, Berjan M2, Thompson S3, Stoykova B4
1ZRx Outcomes Research, Mississauga, ON, Canada, 2ZRx Outcomes Research USA LLC, Rancho 
Cucamonga, CA, USA, 3ZRx Outcomes Research, Berlin, Germany, 4Daiichi Sankyo, Gerrards 
Cross, UK
objeCtives: International Reference Pricing (IRP) is a key cost-containment method 
for health care payers. We have developed based on local experts and publically 
available IRP rules a user-friendly price management tool (Orange) designed 
to enable the real-time forecasting of the global pricing impact of a branded 
launched product price change in a single market. The objective of this analysis is 
to explore, using Orange, the potential impact of price reductions in key EU mar-
kets. Methods: Two price datasets were used to illustrate core features of the 
Orange tool. In the first all prices were set at € 10 and in the second (real life dataset) 
prices were in the range of € 1.78-2.86 (highest for UK followed by DE, ES, IT and FR). 
With each dataset prices were varied for Germany (DE), UK, France (FR), Spain (ES) 
and Italy (IT). Results: A DE price decrease would result in the greatest number of 
reductions elsewhere. A 10% decrease in DE (on € 10) would lead to the same % reduc-
tion in FR, Romania (RO), Russia (RU), Slovenia (SI), Croatia (HR) and Luxembourg (LU) 
and smaller reductions in multiple other countries. A 10% reduction in UK would 
lead mainly to a 10% decrease in FR, RO and HR. A 10% price reduction in FR would 
have greatest impact in HR (13%), SI and RU (10%) and in IT it would be FR, RO and 
